Location History:
- Chicago, IL (US) (1992)
- Gurnee, IL (US) (2002)
Company Filing History:
Years Active: 1992-2002
Title: Innovations and Contributions of John E Stephens
Introduction
John E Stephens is a notable inventor based in Gurnee, IL (US). He has made significant contributions to the field of immunology, particularly in the detection of viral antibodies. With a total of 2 patents, his work has advanced the understanding and diagnosis of certain infectious diseases.
Latest Patents
One of his latest patents is titled "Methods for the detection of HTLV-II antibodies employing novel HTLV-II NRA envelope peptides." This invention relates to a novel human T-cell lymphotropic virus type II (HTLV-II) isolate designated NRA, which was originally isolated from a patient with atypical hairy cell leukemia. The invention focuses on the gp46 and p21 envelope proteins encoded by the env gene, providing methods and kits for the detection of HTLV-II antibodies using these proteins.
Another significant patent by Stephens is "Multilayer solid phase immunoassay support and method of use." This immunoassay is capable of simultaneously detecting multiple antigens or immunoglobulins from one or several infectious agents on a single solid support. The method involves contacting a test sample with a solid support that has immobilized antigens, allowing for the formation and detection of antigen-antibody complexes.
Career Highlights
John E Stephens is associated with Abbott Laboratories Corporation, a leading company in the healthcare sector. His work at Abbott has allowed him to contribute to innovative solutions in diagnostics and immunology.
Collaborations
Throughout his career, Stephens has collaborated with notable colleagues, including Emerson W Chan and Werner Schulze. These collaborations have further enriched his research and development efforts.
Conclusion
John E Stephens has made remarkable contributions to the field of immunology through his innovative patents and work at Abbott Laboratories Corporation. His advancements in the detection of viral antibodies have significant implications for public health and disease management.